TP53 and acute myeloid leukemia: Despite these encouraging results suggesting that pharmacological co-interventions with simvastatin and/or BIO-acetoxime may improve the efficacy of CAR T-cells against TP53-mutant AML, toxicity associated with such high doses of simvastatin as well as the short-lived effect of BIO-acetoxime would raise concerns over their clinical applicability.